1. Home
  2. GKOS vs LEGN Comparison

GKOS vs LEGN Comparison

Compare GKOS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • LEGN
  • Stock Information
  • Founded
  • GKOS 1998
  • LEGN 2014
  • Country
  • GKOS United States
  • LEGN United States
  • Employees
  • GKOS N/A
  • LEGN N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • LEGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • GKOS Health Care
  • LEGN Health Care
  • Exchange
  • GKOS Nasdaq
  • LEGN Nasdaq
  • Market Cap
  • GKOS 5.8B
  • LEGN 5.4B
  • IPO Year
  • GKOS 2015
  • LEGN 2020
  • Fundamental
  • Price
  • GKOS $103.50
  • LEGN $35.64
  • Analyst Decision
  • GKOS Strong Buy
  • LEGN Strong Buy
  • Analyst Count
  • GKOS 13
  • LEGN 13
  • Target Price
  • GKOS $135.15
  • LEGN $75.17
  • AVG Volume (30 Days)
  • GKOS 903.0K
  • LEGN 2.0M
  • Earning Date
  • GKOS 07-30-2025
  • LEGN 08-08-2025
  • Dividend Yield
  • GKOS N/A
  • LEGN N/A
  • EPS Growth
  • GKOS N/A
  • LEGN N/A
  • EPS
  • GKOS N/A
  • LEGN N/A
  • Revenue
  • GKOS $404,523,000.00
  • LEGN $728,303,000.00
  • Revenue This Year
  • GKOS $27.88
  • LEGN $65.49
  • Revenue Next Year
  • GKOS $27.60
  • LEGN $53.76
  • P/E Ratio
  • GKOS N/A
  • LEGN N/A
  • Revenue Growth
  • GKOS 23.92
  • LEGN 112.46
  • 52 Week Low
  • GKOS $77.10
  • LEGN $27.34
  • 52 Week High
  • GKOS $163.71
  • LEGN $60.87
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 61.38
  • LEGN 57.79
  • Support Level
  • GKOS $100.92
  • LEGN $32.42
  • Resistance Level
  • GKOS $106.52
  • LEGN $36.91
  • Average True Range (ATR)
  • GKOS 3.30
  • LEGN 1.42
  • MACD
  • GKOS 0.37
  • LEGN 0.02
  • Stochastic Oscillator
  • GKOS 71.27
  • LEGN 67.58

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: